|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: Hormone-Taking Is Linked to Dementia (or not)From: Joanne Bulley, MD (islesannie@yahoo.com)Tue May 27 21:30:06 2003
Although the Cache County study is an observational study - it is still one more bit of data in this quagmire. I am still PO'd about the fact that the WHI included ONLY those withOUT vasomotor instability. Although I understand the rationale - I do have a patient on the WHI study who had a hyst - and I can tell by examination of her vagina whether she is on Premarin or on the placebo. Dr. George Morely at U of Mich showed us pictures of vulvas and we had to estimate the age based on the clinical exam (picture) - of course none of the pictures included women on HRT - after all it was only 1982! I can't help but think that the women without vasomotor instability are somehow biologically a bit different from those that do have those symptoms. Saying they are the "same population" is like saying because some people do not need an SSRI - no one needs them. Tongue in cheek: because studies of people who don't need SSRIs but are given them in a double blind study have problems without benefits... If you take women who do NOT have the vasomotor (CNS mediated) symptoms - and compare CNS function with or without (cognitive etc) then you likely will find minimal difference between the treated an nontreated. Also - the Cache County study shows a minimum of 10 years of therapy is needed to show the benefit to Alzheimer reduction - and the WHI was only 5.2 years... OK, OK, I'll get off my soapbox!!! Joanne
At Tue, 27 May 2003, Richard Chudacoff, MD wrote:
> JAMA. 2002;288:2123-2129 Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women The Cache County Study Peter P. Zandi, PhD; Michelle C. Carlson, PhD; Brenda L. Plassman, PhD; Kathleen A. Welsh-Bohmer, PhD; Lawrence S. Mayer, MD; David C. Steffens, MD; John C. S. Breitner, MD; for the Cache County Memory Study Investigators JAMA. 2002;288:2123-2129. Context Previous studies have shown a sex-specific increased risk of Alzheimer disease (AD) in women older than 80 years. Basic neuroscience findings suggest that hormone replacement therapy (HRT) could reduce a woman's risk of AD. Epidemiologic findings on AD and HRT are mixed. Objective To examine the relationship between use of HRT and risk of AD among elderly women. Design, Setting, and Participants Prospective study of incident dementia among 1357 men (mean age, 73.2 years) and 1889 women (mean age, 74.5 years) residing in a single county in Utah. Participants were first assessed in 1995-1997, with follow-up conducted in 1998-2000. History of women's current and former use of HRT, as well as of calcium and multivitamin supplements, was ascertained at the initial contact. Main Outcome Measure Diagnosis of incident AD. Results Thirty-five men (2.6%) and 88 women (4.7%) developed AD between the initial interview and time of the follow-up (3 years). Incidence among women increased after age 80 years and exceeded the risk among men of similar age (adjusted hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.22-3.86). Women who used HRT had a reduced risk of AD (26 cases among 1066 women) compared with non-HRT users (58 cases among 800 women) (adjusted HR, 0.59; 95% CI, 0.36-0.96). Risk varied with duration of HRT use, so that a woman's sex-specific increase in risk disappeared entirely with more than 10 years of treatment (7 cases among 427 women). Adjusted HRs were 0.41 (95% CI, 0.17-0.86) for HRT users compared with nonusers and 0.77 (95% CI, 0.31-1.67) compared with men. No similar effect was seen with calcium or multivitamin use. Almost all of the HRT-related reduction in incidence reflected former use of HRT (9 cases among 490 women; adjusted HR, 0.33 [95% CI, 0.15-0.65]). There was no effect with current HRT use (17 cases among 576 women; adjusted HR, 1.08 [95% CI, 0.59-1.91]) unless duration of treatment exceeded 10 years (6 cases among 344 women; adjusted HR, 0.55 [95% CI, 0.21-1.23]). Conclusions Prior HRT use is associated with reduced risk of AD, but there is no apparent benefit with current HRT use unless such use has exceeded 10 years. Author Affiliations: Department of Mental Hygiene, School of Hygiene and Public Health, the Johns Hopkins University, Baltimore, Md (Drs Zandi, Carlson, Mayer, and Breitner); Department of Psychiatry and Behavioral Sciences (Drs Plassman, Welsh-Bohmer, and Steffens), and The Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC (Dr Welsh-Bohmer); Banner Health System, Phoenix, Ariz (Dr Mayer); and VA Puget Sound Health Care System and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Dr Breitner).
-- Joanne Bulley, MD Keene, NH, USA
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Thu Oct 2 04:44:26 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.